REPL Overview
Upcoming Projects (REPL)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (REPL)
-
A discussion of Replimune cemiplimab and the potential of RP1 in combination as a treatment for Cutaneous squamous cell carcinoma (cSCC)
Tickers: REPL, REGN
Executed On: Feb 15, 2023 at 04:30 PM EST -
A discussion of RP1, an oncolytic virus, and its potential in various skin cancers in the IGNYTE trial
Ticker: REPL
Executed On: Dec 21, 2022 at 11:00 AM EST -
Discussing the IGNYTE study and potential of RP1 in combination with nivolumab for treating various cancers, with a focus on Melanoma.
Ticker: REPL
Executed On: Jun 27, 2022 at 04:00 PM EDT -
Discussing the potential of RP1 in combination with Libtayo in patients with Cutaneous squamous cell carcinoma (CSCC)
Tickers: REPL, REGN
Executed On: Mar 09, 2022 at 04:00 PM EST
Expired Projects (REPL)
Upcoming & Overdue Catalysts (REPL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (REPL)
-
Replimune (REPL) Presents Biomarker Study with RP1 and RP2 at the 2021 American Association for Cancer Research Annual (AACR) Meeting
Ticker: REPL
Occurred on: Apr 12, 2021
Strategic Initiatives (REPL)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
